TNP-2092 is under clinical development by TenNor Therapeutics and currently in Phase III for Prosthetic Joint infections. According to GlobalData, Phase III drugs for Prosthetic Joint infections have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how TNP-2092’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TNP-2092 overview

TNP-2092 (CBR-2092) is under development for the treatment of acute bacterial skin and skin structure infection, prosthetic joint infections, biofilm-associated bacterial infections, hepatic encephalopathy, cirrhosis, irritable bowel syndrome, diarrhea, hyperammonemia, and gastrointestinal tract infections including Helicobacter pylori Infections, superbug and diabetic foot infections.. The drug candidate is administered through oral and intravenous route. It is a rifamycin-quinolone based hybrid antibiotic. The drug candidate is a small molecule which acts by targeting RNA polymerase, DNA gyrase and DNA topoisomerase IV. It was also under development for bacterial infections.

TenNor Therapeutics overview

TenNor Therapeutics develops novel drugs for the treatment of infectious diseases. The company’s pipeline Product portfolio includes TNP-2092 IV for the treatment of prosthetic joint infections (PJI); TNP-2092 PO for gastrointestinal tract infections; TNP-2198 for the treatment of bacterial vaginosis and anaerobic infections; MDR-TB for tuberculosis; and MDR-GN for the treatment of infections caused by multidrug resistant gram-negative bacteria. It also carries out research and development activities for developing new drugs. TenNor Therapeutics has collaborations with 3D Bio Optima, Colorado State University, JMI Laboratories, Peking University, and others. The company has operational presence across the globe. TenNor Therapeutics is headquartered in Suzhou, Jiangsu, China.

For a complete picture of TNP-2092’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.